Tineke W H Meijer1, Wenny J M Peeters2, Ludwig J Dubois3, Marike W van Gisbergen3, Rianne Biemans3, Jan-Hendrik Venhuizen4, Paul N Span2, Johan Bussink2. 1. Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology, Radboud university medical center, Nijmegen, the Netherlands. Electronic address: Tineke.vanZon-Meijer@radboudumc.nl. 2. Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology, Radboud university medical center, Nijmegen, the Netherlands. 3. Department of Precision Medicine, The M-Lab, GROW - School for Oncology and Developmental Biology, Maastricht Comprehensive Cancer Centre, Maastricht University Medical Centre, Maastricht, the Netherlands. 4. Department of Cell Biology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, the Netherlands.
Abstract
PURPOSE: Metabolic inhibition might sensitize tumors to irradiation. Here, we examined the effect of lonidamine (several metabolic effects, inhibiting hexokinase amongst others) and/or 968 (glutaminase inhibitor) on tumor cell metabolism, cell growth, cytotoxicity and radiosensitivity in NSCLC cell lines in vitro in relation to histology. MATERIALS AND METHODS: Adeno- (H23, HCC827, H1975) and squamous cell carcinoma (H520, H292, SW900) NSCLC cells were treated with lonidamine and/or 968 for 72 h under physiological levels of glucose (1.5 mM). Cells were irradiated with 0, 4 or 8 Gy. Cell growth of H2B-mCherry transduced cells and cytotoxicity (CellTox™ Green Cytotoxicity Assay) were measured using live cell imaging (IncuCyte). Inhibitory effects on metabolic profiles was determined using the Seahorse XF96 extracellular Flux analyzer. RESULTS: NSCLC cell lines responded differently to glycolysis (lonidamine) and/or glutaminase (968) inhibition, largely corresponding with changes in glycolytic and mitochondrial metabolism upon treatment. Response patterns were not related to histology. 968 was cytotoxic in cell lines with high glutaminase C expression (H1975 and H520), whereas combination treatment was cytotoxic in KRAS mutated cell lines SW900 and H23. H292 and HCC827 were resistant to combination treatment. Treatment with 968 and especially lonidamine resulted in radiosensitization of H292 and HCC827 in terms of decreased relative cell growth and increased cytotoxicity. CONCLUSION: NSCLC is a heterogeneous disease, which is reflected in the response of different cell lines to the treatment (combinations) reported here. Only a part of NSCLC patients may benefit from the combination of radiation therapy and metabolic inhibition, making stratification necessary.
PURPOSE: Metabolic inhibition might sensitize tumors to irradiation. Here, we examined the effect of lonidamine (several metabolic effects, inhibiting hexokinase amongst others) and/or 968 (glutaminase inhibitor) on tumor cell metabolism, cell growth, cytotoxicity and radiosensitivity in NSCLC cell lines in vitro in relation to histology. MATERIALS AND METHODS: Adeno- (H23, HCC827, H1975) and squamous cell carcinoma (H520, H292, SW900) NSCLC cells were treated with lonidamine and/or 968 for 72 h under physiological levels of glucose (1.5 mM). Cells were irradiated with 0, 4 or 8 Gy. Cell growth of H2B-mCherry transduced cells and cytotoxicity (CellTox™ Green Cytotoxicity Assay) were measured using live cell imaging (IncuCyte). Inhibitory effects on metabolic profiles was determined using the Seahorse XF96 extracellular Flux analyzer. RESULTS:NSCLC cell lines responded differently to glycolysis (lonidamine) and/or glutaminase (968) inhibition, largely corresponding with changes in glycolytic and mitochondrial metabolism upon treatment. Response patterns were not related to histology. 968 was cytotoxic in cell lines with high glutaminase C expression (H1975 and H520), whereas combination treatment was cytotoxic in KRAS mutated cell lines SW900 and H23. H292 and HCC827 were resistant to combination treatment. Treatment with 968 and especially lonidamine resulted in radiosensitization of H292 and HCC827 in terms of decreased relative cell growth and increased cytotoxicity. CONCLUSION:NSCLC is a heterogeneous disease, which is reflected in the response of different cell lines to the treatment (combinations) reported here. Only a part of NSCLCpatients may benefit from the combination of radiation therapy and metabolic inhibition, making stratification necessary.
Authors: Michael S Binkley; Young-Jun Jeon; Monica Nesselbush; Everett J Moding; Barzin Y Nabet; Diego Almanza; Christian Kunder; Henning Stehr; Christopher H Yoo; Siyeon Rhee; Michael Xiang; Jacob J Chabon; Emily Hamilton; David M Kurtz; Linda Gojenola; Susie Grant Owen; Ryan B Ko; June Ho Shin; Peter G Maxim; Natalie S Lui; Leah M Backhus; Mark F Berry; Joseph B Shrager; Kavitha J Ramchandran; Sukhmani K Padda; Millie Das; Joel W Neal; Heather A Wakelee; Ash A Alizadeh; Billy W Loo; Maximilian Diehn Journal: Cancer Discov Date: 2020-10-18 Impact factor: 38.272
Authors: Sugandha Bhatia; James Monkman; Tony Blick; Pascal Hg Duijf; Shivashankar H Nagaraj; Erik W Thompson Journal: J Clin Med Date: 2019-08-19 Impact factor: 4.241
Authors: Irini Skaripa-Koukelli; David Hauton; John Walsby-Tickle; Eloïse Thomas; Joshua Owen; Abirami Lakshminarayanan; Sarah Able; James McCullagh; Robert C Carlisle; Katherine A Vallis Journal: Cancer Metab Date: 2021-10-14